Aardvark Therapeutics, Inc. — Form 8-K Summary
Reporting date: October 6, 2026 (filed October 8, 2026). The filing reports a board appointment and does not present quarterly or annual financial results.
Business context and reporting period
Aardvark Therapeutics is a Delaware corporation whose common stock trades on Nasdaq under AARD. The filing concerns a corporate governance change, effective October 7, 2026.
Board appointment and compensation
- The Board appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director.
- Dr. Zhang has more than 25 years of experience in clinical-program design, pivotal-trial analysis, biometrics, and regulatory submissions. He is Chief Strategy Officer of Abivax S.A. and previously held leadership roles at Alumis, MyoKardia, Roche/Genentech, Eli Lilly, and Abbott.
- Under the company’s non-employee director compensation program, he is entitled to $40,000 annual cash compensation, prorated for his service period.
- On October 7, he received an option award with a stated value of $500,000, converted into shares using the option’s per-share grant-date fair value. It vests in 36 monthly installments, subject to continued service, and fully accelerates upon a qualifying change in control while he serves on the Board.
- The company entered into its standard indemnification and advancement agreement with Dr. Zhang. The filing reports no family relationships with company directors or executive officers, no selection arrangement, and no reportable related-party transaction involving him.
Financial performance, outlook, and risks
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance figures, and no guidance or financial outlook. It does not describe new contingencies or material risks.
Most important facts to verify
- Dr. Zhang’s appointment became effective October 7, 2026, and he was designated a Class II director.
- The option’s share count depends on its per-share grant-date fair value; the filing text does not provide a clear share count.
- Confirm the applicable vesting and change-in-control terms in the company’s compensation program and 2025 Equity Incentive Plan.
- The 8-K attaches an October 8, 2026 press release as Exhibit 99.1.